Edition:
United States

Harvard Bioscience Inc (HBIO.OQ)

HBIO.OQ on NASDAQ Stock Exchange Global Market

3.55USD
1:17pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.55
Open
$3.50
Day's High
$3.55
Day's Low
$3.50
Volume
4,018
Avg. Vol
9,928
52-wk High
$3.70
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Harvard Bioscience Q2 adjusted earnings $0.03/shr
Thursday, 28 Jul 2016 06:15am EDT 

Harvard Bioscience Inc : Harvard Bioscience Reports Second Quarter 2016 Financial Results . Updating Full-Year Financial Guidance To Reflect Current Foreign Currency Exchange Rates, Including Impact Of Brexit Uncertainty . Q2 Shr View $0.03, Rev View $26.6 Mln -- Thomson Reuters I/B/E/S . Sees Full-Year 2016 Non-Gaap Diluted Earnings Per Share Of $0.16 To $0.18 . Fy2016 Shr View $0.18, Rev View $109.7 Mln -- Thomson Reuters I/B/E/S . Q2 Gaap Shr Loss $0.02 . Sees Fy 2016 Gaap Shr About $0.00 To $0.02 . Q2 Revenue Fell 9 Pct To $26.1 Mln .Q2 Non-Gaap Shr $0.03.  Full Article

Harvard Bioscience posts Q1 loss of $0.02/share
Thursday, 12 May 2016 06:00am EDT 

Harvard Bioscience Inc : Harvard Bioscience reports first quarter 2016 financial results . Q1 non-GAAP earnings per share $0.05 . Q1 revenue rose 4.7 percent to $27 million . Q1 GAAP loss per share $0.02 . Reaffirming its financial guidance for full year 2016 .Sees FY 2016 non-GAAP earnings per share $0.17 to $0.19.  Full Article

Harvard Bioscience files for non-timely 10-Q
Tuesday, 10 May 2016 05:53pm EDT 

Harvard Bioscience Inc :Files for non-timely 10-Q - SEC filing.  Full Article

Harvard Bioscience Inc Delays 10-K Filing, Cites Employee Theft - MIDTRD
Monday, 14 Mar 2016 04:13pm EDT 

Harvard Bioscience Inc:Harvard Bioscience (HBIO) disclosed it will delay filing its annual report on Form 10-K for the fiscal year ended December 31, 2015 - MIDTRD.The Form 10-K filing, as well as the earnings release, have been delayed due to the timing of a forensic investigation initiated by the company following its discovery.based upon preliminary findings, that an employee at Denville Scientific, Inc., one of its wholly-owned subsidiaries (Denville), appears to have embezzled money from the Company and manipulated certain records in an attempt to conceal the theft.Upon detecting the embezzlement, the company commenced an investigation, including the engagement of a forensic accounting expert to conduct an investigation to determine the scope and amount of the inappropriate activity.The company believes, based upon the preliminary results of such forensic investigation, that the embezzlement was limited to the Denville financial statements, the aggregate amount of embezzled funds was less than $50,000.  Full Article

BRIEF-Harvard Bioscience says First Light Asset Management reports 10.3 pct passive stake in Harvard - SEC Filing

* First Light Asset Management Reports 10.3 Pct Passive Stake In Harvard Bioscience Inc As of june 30 - SEC Filing Source text for Eikon: Further company coverage: